The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.

Friday initiated legal action against the three largest prescription drug benefit managers (PBMs) in the U.S.—Caremark Rx, ...

The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in ...

Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts, and Indiana’s ...

Cigna may have the edge with smaller footprint and focused approach, but all three giants face risks from FTC's lawsuit over inflated insulin prices.

The FTC accuses the largest pharmacy benefit manager companies of unfairly boosting prices on prescription drugs.

PBMs, like Optum Rx, are the key counterweight to pharmaceutical companies’ otherwise unchecked monopoly power to set and raise drug prices.

The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.